Literature DB >> 17616579

Cellular cofactors affecting hepatitis C virus infection and replication.

Glenn Randall1, Maryline Panis, Jacob D Cooper, Timothy L Tellinghuisen, Karen E Sukhodolets, Sebastien Pfeffer, Markus Landthaler, Pablo Landgraf, Sherry Kan, Brett D Lindenbach, Minchen Chien, David B Weir, James J Russo, Jingyue Ju, Michael J Brownstein, Robert Sheridan, Chris Sander, Mihaela Zavolan, Thomas Tuschl, Charles M Rice.   

Abstract

Recently identified hepatitis C virus (HCV) isolates that are infectious in cell culture provide a genetic system to evaluate the significance of virus-host interactions for HCV replication. We have completed a systematic RNAi screen wherein siRNAs were designed that target 62 host genes encoding proteins that physically interact with HCV RNA or proteins or belong to cellular pathways thought to modulate HCV infection. This includes 10 host proteins that we identify in this study to bind HCV NS5A. siRNAs that target 26 of these host genes alter infectious HCV production >3-fold. Included in this set of 26 were siRNAs that target Dicer, a principal component of the RNAi silencing pathway. Contrary to the hypothesis that RNAi is an antiviral pathway in mammals, as has been reported for subgenomic HCV replicons, siRNAs that target Dicer inhibited HCV replication. Furthermore, siRNAs that target several other components of the RNAi pathway also inhibit HCV replication. MicroRNA profiling of human liver, human hepatoma Huh-7.5 cells, and Huh-7.5 cells that harbor replicating HCV demonstrated that miR-122 is the predominant microRNA in each environment. miR-122 has been previously implicated in positively regulating the replication of HCV genotype 1 replicons. We find that 2'-O-methyl antisense oligonucleotide depletion of miR-122 also inhibits HCV genotype 2a replication and infectious virus production. Our data define 26 host genes that modulate HCV infection and indicate that the requirement for functional RNAi for HCV replication is dominant over any antiviral activity this pathway may exert against HCV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616579      PMCID: PMC1937561          DOI: 10.1073/pnas.0704894104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  63 in total

1.  Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.

Authors:  Catherine L Jopling; Minkyung Yi; Alissa M Lancaster; Stanley M Lemon; Peter Sarnow
Journal:  Science       Date:  2005-09-02       Impact factor: 47.728

2.  Anti-apoptotic function of a microRNA encoded by the HSV-1 latency-associated transcript.

Authors:  A Gupta; J J Gartner; P Sethupathy; A G Hatzigeorgiou; N W Fraser
Journal:  Nature       Date:  2006-05-31       Impact factor: 49.962

3.  miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1.

Authors:  Jinhong Chang; Emmanuelle Nicolas; Debora Marks; Chris Sander; Anthony Lerro; Marie Annick Buendia; Chunxiao Xu; William S Mason; Thomas Moloshok; Roque Bort; Kenneth S Zaret; John M Taylor
Journal:  RNA Biol       Date:  2004-07-01       Impact factor: 4.652

Review 4.  Applications of interaction traps/two-hybrid systems to biotechnology research.

Authors:  A R Mendelsohn; R Brent
Journal:  Curr Opin Biotechnol       Date:  1994-10       Impact factor: 9.740

5.  Hepatitis C virus core protein: carboxy-terminal boundaries of two processed species suggest cleavage by a signal peptide peptidase.

Authors:  P Hüssy; H Langen; J Mous; H Jacobsen
Journal:  Virology       Date:  1996-10-01       Impact factor: 3.616

6.  Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection.

Authors:  Glenn Randall; Limin Chen; Maryline Panis; Andrew K Fischer; Brett D Lindenbach; Jing Sun; Jenny Heathcote; Charles M Rice; Aled M Edwards; Ian D McGilvray
Journal:  Gastroenterology       Date:  2006-08-22       Impact factor: 22.682

7.  Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.

Authors:  Gunter Meister; Markus Landthaler; Agnieszka Patkaniowska; Yair Dorsett; Grace Teng; Thomas Tuschl
Journal:  Mol Cell       Date:  2004-07-23       Impact factor: 17.970

8.  Interaction of polypyrimidine tract-binding protein with the 5' noncoding region of the hepatitis C virus RNA genome and its functional requirement in internal initiation of translation.

Authors:  N Ali; A Siddiqui
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase.

Authors:  K E Reed; J Xu; C M Rice
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

10.  Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication.

Authors:  Matthew J Evans; Charles M Rice; Stephen P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

View more
  281 in total

1.  Poly(C)-binding protein 2 interacts with sequences required for viral replication in the hepatitis C virus (HCV) 5' untranslated region and directs HCV RNA replication through circularizing the viral genome.

Authors:  Linya Wang; King-Song Jeng; Michael M C Lai
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  The interferon inducible gene: Viperin.

Authors:  Katherine A Fitzgerald
Journal:  J Interferon Cytokine Res       Date:  2010-12-12       Impact factor: 2.607

Review 3.  MicroRNAs regulating lipid metabolism in atherogenesis.

Authors:  K J Rayner; C Fernandez-Hernando; K J Moore
Journal:  Thromb Haemost       Date:  2012-01-25       Impact factor: 5.249

4.  Identification of novel host factors via conserved domain search: Cns1 cochaperone is a novel restriction factor of tombusvirus replication in yeast.

Authors:  Jing-Yi Lin; Peter D Nagy
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

Review 5.  MicroRNAs and liver disease.

Authors:  Thomas A Kerr; Kevin M Korenblat; Nicholas O Davidson
Journal:  Transl Res       Date:  2011-02-02       Impact factor: 7.012

6.  RNA triphosphatase DUSP11 enables exonuclease XRN-mediated restriction of hepatitis C virus.

Authors:  Rodney P Kincaid; Victor L Lam; Rachel P Chirayil; Glenn Randall; Christopher S Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

Review 7.  Host-targeting agents in the treatment of hepatitis C: a beginning and an end?

Authors:  James M Baugh; Jose A Garcia-Rivera; Philippe A Gallay
Journal:  Antiviral Res       Date:  2013-09-30       Impact factor: 5.970

8.  DDX3 DEAD-Box RNA helicase inhibits hepatitis B virus reverse transcription by incorporation into nucleocapsids.

Authors:  Haifeng Wang; Seahee Kim; Wang-Shick Ryu
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  Intramembrane processing by signal peptide peptidase regulates the membrane localization of hepatitis C virus core protein and viral propagation.

Authors:  Kiyoko Okamoto; Yoshio Mori; Yasumasa Komoda; Toru Okamoto; Masayasu Okochi; Masatoshi Takeda; Tetsuro Suzuki; Kohji Moriishi; Yoshiharu Matsuura
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication.

Authors:  Lucie Goueslain; Khaled Alsaleh; Pauline Horellou; Philippe Roingeard; Véronique Descamps; Gilles Duverlie; Yann Ciczora; Czeslaw Wychowski; Jean Dubuisson; Yves Rouillé
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.